{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:14:45Z","timestamp":1788239685636,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the JSPS Fujita Memorial Fund for Medical Research"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K09480"],"award-info":[{"award-number":["JP21K09480"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aspirin exhibits potential as a repurposed agent for preventing and treating cancer, specifically\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -mutated (MT) colorectal cancer. However, the fundamental biological reasons for the particular antitumor activity of aspirin against\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT colorectal cancer are not yet fully elucidated. We have previously established that aspirin relates to glutamine metabolism in\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT colorectal cancer. In evaluating the antitumor effects of aspirin, it is essential to consider the tumor growth environment, such as hypoxia. The impact of the tumor microenvironment on aspirin efficacy remains unknown. Therefore, we aimed to investigate the mechanisms through which hypoxia influences aspirin- associated intracellular glutamine accumulation in\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT colorectal cancer cell lines. Connectivity Map analysis was used to explore the associations of aspirin with biological pathways in HT-29 (\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT) cells. RNA sequencing was performed on\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -wild type (WT)\/mutant isogenic SW48 cell lines to assess aspirin\u2019s effects under hypoxic conditions. Targeted metabolomics was employed to measure intracellular glutamine levels in\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT HCT116 cells following aspirin treatment and hypoxic stimulation. Bioinformatic analysis revealed associations of aspirin with amino acid metabolism and hypoxic pathways. Under hypoxic conditions, aspirin enhanced amino acid uptake in\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT cells. Targeted metabolomics showed that aspirin treatment and hypoxic stimulation additively upregulated intracellular glutamine levels in\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT cells. This increase was reversed by V-9302, an inhibitor of the glutamine transporter ASCT2, which demonstrated antitumor potential in combination with aspirin. Our findings suggest that the combination of aspirin and hypoxia significantly enhances intracellular glutamine accumulation in\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    -MT colorectal cancer under hypoxic conditions, emphasizing glutamine metabolism as a potential therapeutic target to enhance aspirin\u2019s efficacy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-42753-z","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:01:30Z","timestamp":1774346490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Nodoka","family":"Umezaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-0379","authenticated-orcid":false,"given":"Shogen","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3183-4871","authenticated-orcid":false,"given":"Yoshiyuki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-6803","authenticated-orcid":false,"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-1161","authenticated-orcid":false,"given":"Motoki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-0827","authenticated-orcid":false,"given":"Kiichi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Sugie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Sekimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"42753_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/cells8070726","volume":"8","author":"A Vall\u00e9e","year":"2019","unstructured":"Vall\u00e9e, A., Lecarpentier, Y. & Vall\u00e9e, J. N. Targeting the Canonical WNT\/\u03b2-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs. Cells 8, 726 (2019).","journal-title":"Cells"},{"key":"42753_CR2","doi-asserted-by":"crossref","unstructured":"Wong, R. S. Y. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. Adv Pharmacol Sci 3418975. (2019).","DOI":"10.1155\/2019\/3418975"},{"key":"42753_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-13-2563","volume":"20","author":"D Tougeron","year":"2014","unstructured":"Tougeron, D., Sha, D., Manthravadi, S. & Sinicrope, F. A. Aspirin and colorectal cancer: back to the future. Clin. Cancer Res. 20, 1087\u20131094 (2014).","journal-title":"Clin. Cancer Res."},{"key":"42753_CR4","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1038\/srep07896","volume":"5","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP). Sci. Rep. 5, 7896 (2015).","journal-title":"Sci. Rep."},{"key":"42753_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo, K. & U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 164, 836\u2013845 (2016).","journal-title":"Ann. Intern. Med."},{"key":"42753_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M15-2129","volume":"164","author":"SP Dehmer","year":"2016","unstructured":"Dehmer, S. P., Maciosek, M. V., Flottemesch, T. J., LaFrance, A. B. & Whitlock, E. P. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med. 164, 777\u2013786 (2016).","journal-title":"Ann. Intern. Med."},{"key":"42753_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31\u201341 (2011).","journal-title":"Lancet"},{"key":"42753_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591\u20131601 (2012).","journal-title":"Lancet"},{"key":"42753_CR9","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","volume":"367","author":"X Liao","year":"2012","unstructured":"Liao, X. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl. J. Med. 367, 1596\u20131606 (2012).","journal-title":"N Engl. J. Med."},{"key":"42753_CR10","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","volume":"31","author":"E Domingo","year":"2013","unstructured":"Domingo, E. et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31, 4297\u20134305 (2013).","journal-title":"J. Clin. Oncol."},{"key":"42753_CR11","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.23.01680","volume":"42","author":"JA Nowak","year":"2024","unstructured":"Nowak, J. A. et al. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB\/SWOG 80702 (Alliance). J. Clin. Oncol. 42, 2853\u20132859 (2024).","journal-title":"J. Clin. Oncol."},{"key":"42753_CR12","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1158\/1078-0432.CCR-24-4048","volume":"31","author":"U G\u00fcller","year":"2025","unstructured":"G\u00fcller, U. et al. Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41\/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. Clin. Cancer Res. 31, 3142\u20133149 (2025).","journal-title":"Clin. Cancer Res."},{"key":"42753_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2504650","volume":"393","author":"A Martling","year":"2025","unstructured":"Martling, A. et al. Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. N Engl. J. Med. 393, 1051\u20131064 (2025).","journal-title":"N Engl. J. Med."},{"key":"42753_CR14","doi-asserted-by":"publisher","first-page":"87379","DOI":"10.18632\/oncotarget.20972","volume":"8","author":"M Gu","year":"2017","unstructured":"Gu, M. et al. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget 8, 87379\u201387389 (2017).","journal-title":"Oncotarget"},{"key":"42753_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1158\/1940-6207.CAPR-16-0175","volume":"10","author":"TJ Zumwalt","year":"2017","unstructured":"Zumwalt, T. J. et al. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prev. Res. (Phila). 10, 208\u2013218 (2017).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"42753_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","volume":"69","author":"A Sartore-Bianchi","year":"2009","unstructured":"Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851\u20131857 (2009).","journal-title":"Cancer Res."},{"key":"42753_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41419-018-0776-6","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell. Death Dis. 9, 739 (2018).","journal-title":"Cell. Death Dis."},{"key":"42753_CR18","doi-asserted-by":"publisher","first-page":"11971","DOI":"10.1038\/ncomms11971","volume":"7","author":"Y Hao","year":"2016","unstructured":"Hao, Y. et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat. Commun. 7, 11971 (2016).","journal-title":"Nat. Commun."},{"key":"42753_CR19","doi-asserted-by":"publisher","first-page":"E3434","DOI":"10.1073\/pnas.1617922114","volume":"114","author":"N Ilic","year":"2017","unstructured":"Ilic, N. et al. PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc. Natl. Acad. Sci. U S A. 114, E3434\u2013E3443 (2017).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"42753_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.gendis.2016.09.001","volume":"3","author":"X Feng","year":"2016","unstructured":"Feng, X., Hao, Y. & Wang, Z. Targeting glutamine metabolism in PIK3CA mutant colorectal cancers. Genes Dis. 3, 241\u2013243 (2016).","journal-title":"Genes Dis."},{"key":"42753_CR21","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/cancers12051097","volume":"12","author":"S Boku","year":"2020","unstructured":"Boku, S. et al. Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition. Cancers (Basel). 12, 1097 (2020).","journal-title":"Cancers (Basel)"},{"key":"42753_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399\u2013408 (2012).","journal-title":"Cell"},{"key":"42753_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrclinonc.2011.83","volume":"8","author":"K De Bock","year":"2011","unstructured":"De Bock, K., Mazzone, M. & Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8, 393\u2013404 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"42753_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0076-6879(04)81023-1","volume":"381","author":"P Vaupel","year":"2004","unstructured":"Vaupel, P., Mayer, A. & H\u00f6ckel, M. Tumor hypoxia and malignant progression. Methods Enzymol. 381, 335\u2013354 (2004).","journal-title":"Methods Enzymol."},{"key":"42753_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/carcin\/bgp014","volume":"30","author":"A Greenhough","year":"2009","unstructured":"Greenhough, A. et al. The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30, 377\u2013386 (2009).","journal-title":"Carcinogenesis"},{"key":"42753_CR26","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1158\/0008-5472.CAN-06-0425","volume":"66","author":"A Kaidi","year":"2006","unstructured":"Kaidi, A., Qualtrough, D., Williams, A. C. & Paraskeva, C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 66, 6683\u20136691 (2006).","journal-title":"Cancer Res."},{"key":"42753_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrd1929","volume":"5","author":"JA Mitchell","year":"2006","unstructured":"Mitchell, J. A. & Warner, T. D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discov. 5, 75\u201386 (2006).","journal-title":"Nat. Rev. Drug Discov"},{"key":"42753_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2018.05.008","volume":"832","author":"X Liu","year":"2018","unstructured":"Liu, X. et al. Hypoxia-induced upregulation of Orai1 drives colon cancer invasiveness and angiogenesis. Eur. J. Pharmacol. 832, 1\u201310 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"42753_CR29","first-page":"1","volume":"9","author":"E Ortiz-Prado","year":"2019","unstructured":"Ortiz-Prado, E., Dunn, J. F., Vasconez, J., Castillo, D. & Viscor, G. Partial pressure of oxygen in the human body: a general review. Am. J. Blood Res. 9, 1\u201314 (2019).","journal-title":"Am. J. Blood Res."},{"key":"42753_CR30","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935 (2006).","journal-title":"Science"},{"key":"42753_CR31","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"42753_CR32","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.3352573","author":"Y Hiraoka","year":"2019","unstructured":"Hiraoka, Y. et al. ikra: RNAseq pipeline centered on Salmon. Zenodo https:\/\/doi.org\/10.5281\/zenodo.3352573 (2019).","journal-title":"Zenodo"},{"key":"42753_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. Nat. Methods. 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"42753_CR34","doi-asserted-by":"publisher","unstructured":"Krueger, F. et al. FelixKrueger\/TrimGalore: v0.6.10 - add default decompression path. Zenodo (2023). https:\/\/doi.org\/10.5281\/zenodo.7598955","DOI":"10.5281\/zenodo.7598955"},{"key":"42753_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10\u201312 (2011).","journal-title":"EMBnet J."},{"key":"42753_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/978-1-0716-1307-8_22","volume":"2284","author":"X Ge","year":"2021","unstructured":"Ge, X. iDEP Web Application for RNA-Seq Data Analysis. Methods Mol. Biol. 2284, 417\u2013443 (2021).","journal-title":"Methods Mol. Biol."},{"key":"42753_CR37","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"42753_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbrc.2021.10.072","volume":"584","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto, T., Sato, K., Yamaguchi, M., Mitamura, K. & Taga, A. Development of simultaneous quantitative analysis of tricarboxylic acid cycle metabolites to identify specific metabolites in cancer cells by targeted metabolomic approach. Biochem. Biophys. Res. Commun. 584, 53\u201359 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"42753_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer. 16, 619\u2013634 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"42753_CR40","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890\u2013901 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"42753_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nm.4464","volume":"24","author":"ML Schulte","year":"2018","unstructured":"Schulte, M. L. et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat. Med. 24, 194\u2013202 (2018).","journal-title":"Nat. Med."},{"key":"42753_CR42","doi-asserted-by":"publisher","first-page":"10551","DOI":"10.1021\/jm301191p","volume":"55","author":"K Shukla","year":"2012","unstructured":"Shukla, K. et al. Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors. J. Med. Chem. 55, 10551\u201310563 (2012).","journal-title":"J. Med. Chem."},{"key":"42753_CR43","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br. J. Radiol. 87, 20130676 (2014).","journal-title":"Br. J. Radiol."},{"key":"42753_CR44","first-page":"5830","volume":"59","author":"H Zhong","year":"1999","unstructured":"Zhong, H. et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59, 5830\u20135835 (1999).","journal-title":"Cancer Res."},{"key":"42753_CR45","doi-asserted-by":"publisher","first-page":"E10869","DOI":"10.1073\/pnas.1808314115","volume":"115","author":"I Amelio","year":"2018","unstructured":"Amelio, I. et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc. Natl. Acad. Sci. U S A. 115, E10869\u2013E10878 (2018).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"42753_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.gastro.2022.11.029","volume":"164","author":"S Yang","year":"2023","unstructured":"Yang, S. et al. Integrated Multi-Omics Landscape of Liver Metastases. Gastroenterology 164, 407\u2013423e17 (2023).","journal-title":"Gastroenterology"},{"key":"42753_CR47","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1126\/science.aam9305","volume":"358","author":"JB Spinelli","year":"2017","unstructured":"Spinelli, J. B. et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science 358, 941\u2013946 (2017).","journal-title":"Science"},{"key":"42753_CR48","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the Intersections between Metabolism and Cancer Biology. Cell 168, 657\u2013669 (2017).","journal-title":"Cell"},{"key":"42753_CR49","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2010.05.008","volume":"38","author":"RT Abraham","year":"2010","unstructured":"Abraham, R. T. & Eng, C. H. A metabolic (re-)balancing act. Mol. Cell. 38, 481\u2013482 (2010).","journal-title":"Mol. Cell."},{"key":"42753_CR50","doi-asserted-by":"publisher","first-page":"e56749","DOI":"10.7554\/eLife.56749","volume":"9","author":"H Jin","year":"2020","unstructured":"Jin, H. et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife 9, e56749 (2020).","journal-title":"Elife"},{"key":"42753_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.redox.2015.01.002","volume":"4","author":"H Sies","year":"2015","unstructured":"Sies, H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 4, 180\u2013183 (2015).","journal-title":"Redox Biol."},{"key":"42753_CR52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes, J. D., Dinkova-Kostova, A. T. & Tew, K. D. Oxidative Stress in Cancer. Cancer Cell. 38, 167\u2013197 (2020).","journal-title":"Cancer Cell."},{"key":"42753_CR53","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.lfs.2004.10.052","volume":"76","author":"D Costa","year":"2005","unstructured":"Costa, D., Gomes, A., Reis, S., Lima, J. L. F. C. & Fernandes, E. Hydrogen peroxide scavenging activity by non-steroidal anti-inflammatory drugs. Life Sci. 76, 2841\u20132848 (2005).","journal-title":"Life Sci."},{"key":"42753_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/A:1006994800272","volume":"194","author":"S Blau","year":"1999","unstructured":"Blau, S., Rubinstein, A., Bass, P., Singaram, C. & Kohen, R. Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Mol. Cell. Biochem. 194, 185\u2013191 (1999).","journal-title":"Mol. Cell. Biochem."},{"key":"42753_CR55","doi-asserted-by":"publisher","first-page":"27307","DOI":"10.1074\/jbc.274.38.27307","volume":"274","author":"Y Yamamoto","year":"1999","unstructured":"Yamamoto, Y., Yin, M. J., Lin, K. M. & Gaynor, R. B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274, 27307\u201327314 (1999).","journal-title":"J. Biol. Chem."},{"key":"42753_CR56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40170-023-00318-y","volume":"11","author":"AK Holt","year":"2023","unstructured":"Holt, A. K. et al. Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition. Cancer Metab. 11, 18 (2023).","journal-title":"Cancer Metab."},{"key":"42753_CR57","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1172\/JCI78239","volume":"125","author":"K Tanaka","year":"2015","unstructured":"Tanaka, K. et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J. Clin. Invest. 125, 1591\u20131602 (2015).","journal-title":"J. Clin. Invest."},{"key":"42753_CR58","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ccell.2018.04.002","volume":"33","author":"M Momcilovic","year":"2018","unstructured":"Momcilovic, M. et al. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer Cell. 33, 905\u2013921e5 (2018).","journal-title":"Cancer Cell."},{"key":"42753_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0016-5085(00)70417-3","volume":"118","author":"JM Rhoads","year":"2000","unstructured":"Rhoads, J. M. et al. Glutamine metabolism stimulates intestinal cell MAPKs by a cAMP-inhibitable, Raf-independent mechanism. Gastroenterology 118, 90\u2013100 (2000).","journal-title":"Gastroenterology"},{"key":"42753_CR60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamainternmed.2014.511","volume":"174","author":"MS Reimers","year":"2014","unstructured":"Reimers, M. S. et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern. Med. 174, 732\u2013739 (2014).","journal-title":"JAMA Intern. Med."},{"key":"42753_CR61","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","volume":"21","author":"SA Kerk","year":"2021","unstructured":"Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M. & Lyssiotis, C. A. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat. Rev. Cancer. 21, 510\u2013525 (2021).","journal-title":"Nat. Rev. Cancer"}],"updated-by":[{"DOI":"10.1038\/s41598-026-65164-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42753-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42753-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42753-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:20:52Z","timestamp":1788236452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42753-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42753"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42753-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-65164-6","URL":"https:\/\/doi.org\/10.1038\/s41598-026-65164-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human and\/or animal participants performed by any of the authors.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"9202"}}